Form 8-K

8-K — Amneal Pharmaceuticals, Inc.

Accession: 0001723128-26-000019

Filed: 2026-05-07

Period: 2026-05-07

CIK: 0001723128

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — amrx-20260507.htm (Primary)

EX-99.1 (amrx-q12026ex991.htm)

GRAPHIC (image.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: amrx-20260507.htm · Sequence: 1

amrx-20260507

false000172312800017231282026-05-072026-05-07

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 7, 2026

AMNEAL PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware 001-38485 93-4225266

(State or other jurisdiction

of incorporation) (Commission File Number) (IRS Employer

Identification No.)

400 Crossing Blvd

Bridgewater, NJ 08807

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (908) 947-3120

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered

Class A Common Stock, par value $0.01 per share AMRX The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On May 7, 2026, Amneal Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its results for the first quarter ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

The information in this report furnished pursuant to Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended (the "Securities Act"), if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibits are furnished herewith:

Exhibit No. Description

99.1

Press release issued May 7, 2026.

104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 7, 2026

AMNEAL PHARMACEUTICALS, INC.

By: /s/ Anastasios Konidaris

Name: Anastasios Konidaris

Title: Executive Vice President and Chief Financial Officer

(Principal Financial and Accounting Officer)

EX-99.1

Filename: amrx-q12026ex991.htm · Sequence: 2

Document

Exhibit 99.1

AMNEAL REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

‒ Q1 2026 Net Revenue of $723 million; GAAP Net Income of $62 million; Diluted Income per Share of $0.19 ‒

‒ Adjusted EBITDA of $202 million; Adjusted Diluted EPS of $0.27 ‒

‒ No Change from Preliminary Results Previously Announced on April 22, 2026 ‒

‒ Affirms Previously Announced Increase in 2026 Full Year Guidance ‒

BRIDGEWATER, NJ, May 7, 2026 - Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the first quarter ended March 31, 2026.

“Amneal delivered a very strong start to 2026, reflecting the strength of our diversified business and multiple growth drivers across the portfolio. Our Specialty business continues to perform exceptionally well, led by CREXONT® and the recent launch of BREKIYA® autoinjector, alongside a strong cadence of key launches in Affordable Medicines. We are entering the Kashiv transaction from a position of strength, at a time when we see an extended period of accelerated growth ahead with no shortage of opportunities across our core businesses. Combined with our very strong first quarter results, we are pleased to affirm our previously announced increase in our full year 2026 guidance,” said Chirag and Chintu Patel, Co-Founders and Co-Chief Executive Officers of Amneal.

First Quarter 2026 Results

Net revenue in the first quarter of 2026 was $723 million, an increase of 4% compared to $695 million in the first quarter of 2025. Specialty net revenue increased 23%, driven by key branded products, including CREXONT®, BREKIYA® autoinjector, and UNITHROID®. Affordable Medicines net revenue increased 2%, driven by strong performance of our complex portfolio, including women’s health and ADHD medicines. AvKARE net revenue declined 4% as growth in the government channel was offset by a decline in the low margin distribution channel. This continued portfolio shift drove a 750 basis point and 510 basis point increase in gross margin and adjusted gross margin, respectively, in the first quarter of 2026, compared to the prior year.

Net income attributable to Amneal Pharmaceuticals, Inc. was $62 million in the first quarter of 2026 compared to net income of $12 million in the first quarter of 2025, an increase of 411%, reflecting higher revenue and gross profit.

Adjusted EBITDA in the first quarter of 2026 was $202 million, an increase of 19% compared to the first quarter of 2025, reflecting higher revenue and gross profit.

Diluted income per share in the first quarter of 2026 was $0.19 compared to diluted income per share of $0.04 for the first quarter of 2025, an increase of 375%, due to the aforementioned factors. Adjusted diluted earnings per share in the first quarter of 2026 was $0.27, an increase of 29% compared to $0.21 for the first quarter of 2025.

The Company presents GAAP and adjusted (non-GAAP) quarterly results. Please refer to the “Non-GAAP Financial Measures” section and the accompanying GAAP to non-GAAP reconciliation tables for more information.

Affirming Previously Announced (on April 22, 2026) Increased 2026 Full Year Guidance

Net revenue

$3.05 billion - $3.15 billion

Adjusted EBITDA (1)

$740 million - $770 million

Adjusted diluted EPS (2)

$0.95 - $1.05

Operating cash flow (3)

$350 million - $400 million

Operating cash flow, excluding discrete items (4)

$375 million - $425 million

Capital expenditures (5)

~$110 million

(1)Includes 100% of adjusted EBITDA from AvKARE. See also “Non-GAAP Financial Measures” below.

(2)Accounts for 35% non-controlling interest in AvKARE. Assumes approximately 330 million weighted-average diluted shares outstanding for the year ending December 31, 2026.

(3)Represents cash provided by operating activities.

(4)Excludes discrete items such as legal settlement payments.

(5)Reflects estimated capital expenditures, net of expected contributions from an alliance party.

Amneal’s 2026 estimates are based on management’s current expectations, including with respect to prescription trends, pricing levels, the timing of future product launches, the costs incurred and benefits realized of restructuring activities, and our long-term strategy. The Company’s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The Company cannot provide a reconciliation between non-GAAP projections and the most directly comparable measures in accordance with GAAP without unreasonable efforts because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items required for the reconciliation. The items include, but are not limited to, acquisition-related expenses, restructuring expenses and benefits, asset impairments, legal settlements, and other gains and losses. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results.

About Amneal

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Amneal was founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, and built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex generic, specialty and biosimilar medicines, delivering more than 160 million prescriptions annually, primarily in the United States. Our Affordable Medicines segment spans retail generics, injectables, and biosimilars. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For additional information, please visit amneal.com and follow us on LinkedIn.

Cautionary Statement on Forward-Looking Statements

Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance; statements regarding our positioning and potential growth, statements regarding our ability to create long-term value, and other non-historical statements. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements.

The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events, including with respect to future market conditions, company performance and financial results, operational investments, business prospects, new strategies and growth initiatives, the competitive environment, and other events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company.

Such risks and uncertainties include, but are not limited to: risks related to our proposed transaction to acquire membership interests of Kashiv BioSciences, LLC (“Kashiv”), our ability to successfully develop, license, acquire and commercialize new products on a timely basis; the competition we face in the pharmaceutical industry from brand and generic drug product companies, and the impact of that competition on our ability to set prices; our ability to obtain exclusive marketing rights for our products; the impact of illegal distribution and sale by third parties of counterfeit versions of our products or stolen products; the impact of negative market perceptions of us and the safety and quality of our products; our revenues are derived from the sales of a limited number of products, a substantial portion of which are through a limited number of customers; the continuing trend of consolidation of certain customer groups; the impact of supply chain disruption; the imposition of tariffs may adversely affect our business, results of operations and financial condition; a U.S. government shutdown could adversely impact our regulatory, operational and financial performance; legal, regulatory and legislative efforts by our brand competitors to deter competition from our generic alternatives; our dependence on information technology systems and infrastructure and the potential for cybersecurity incidents, and risks associated with artificial intelligence; the impact of a prolonged business interruption within our supply chain; our ability to attract, hire and retain highly skilled personnel; risks related to federal regulation of arrangements between manufacturers of branded and generic products; our reliance on certain licenses to proprietary technologies from time to time; the significant amount of resources we expend on research and development; the risk of claims brought against us by third parties; risks related to changes in the regulatory environment, including U.S. federal and state laws related to government contracting, healthcare fraud abuse and health information privacy and security and changes in such laws; changes to Food and Drug Administration product approval requirements and review processes; the impact of healthcare reform and changes in coverage and reimbursement levels and funding by governmental authorities and other third-party payers; our ability to identify, make and integrate acquisitions or investments in complementary businesses

and products on advantageous terms; our dependence on third-party agreements for a portion of our product offerings; our potential expansion into additional international markets subjecting us to increased regulatory, economic, social and political uncertainties; the impact of global economic, political or other catastrophic events; our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future, and the impact of interest rate fluctuations on such indebtedness; our obligations under a tax receivable agreement may be significant; and the high concentration of ownership of our Class A common stock by the Amneal Group. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.

Non-GAAP Financial Measures

This release includes certain non-GAAP financial measures, including EBITDA, adjusted EBITDA, adjusted net income, adjusted diluted EPS, adjusted gross margin, adjusted operating income, net debt, gross leverage, and net leverage, which are intended as supplemental measures of the Company’s performance that are not required by or presented in accordance with GAAP.

Management uses these non-GAAP measures internally to evaluate and manage the Company’s operations and to better understand its business because they facilitate a comparative assessment of the Company’s operating performance relative to its performance based on results calculated under GAAP. These non-GAAP measures also isolate the effects of some items that vary from period to period without any correlation to core operating performance and eliminate certain charges that management believes do not reflect the Company’s operations and underlying operational performance. The compensation committee of the Company’s board of directors also uses certain of these measures to evaluate management’s performance and set its compensation. The Company believes that these non-GAAP measures also provide useful information to investors regarding certain financial and business trends relating to the Company’s financial condition and operating results facilitates an evaluation of the financial performance of the Company and its operations on a consistent basis. Providing this information therefore allows investors to make independent assessments of the Company’s financial performance, results of operations, cash flows, net leverage and trends while viewing the information through the eyes of management.

These non-GAAP measures are subject to limitations. The non-GAAP measures presented in this release may not be comparable to similarly titled measures used by other companies because other companies may not calculate one or more in the same manner. Additionally, the non-GAAP performance measures exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements; do not reflect changes in, or cash requirements for, working capital needs; and do not reflect interest expense, or the requirements necessary to service interest or principal payments on debt. Further, our historical adjusted results are not intended to project our adjusted results of operations or financial position for any future period. To compensate for these limitations, management presents and considers these non-GAAP measures in conjunction with the Company’s GAAP results; no non-GAAP measure should be considered in isolation from or as alternatives to any measure determined in accordance with GAAP. Readers should review the reconciliations included below, and should not rely on any single financial measure to evaluate the Company’s business.

A reconciliation of each historical non-GAAP measure to the most directly comparable GAAP measure is set forth below.

Contact

Anthony DiMeo

VP, Investor Relations

anthony.dimeo@amneal.com

Amneal Pharmaceuticals, Inc.

Consolidated Statements of Operations

(unaudited; in thousands, except per share amounts)

Three Months Ended March 31,

2026 2025

Net revenue $ 722,519 $ 695,420

Cost of goods sold 402,406 439,529

Gross profit 320,113 255,891

Selling, general and administrative 138,860 118,288

Research and development 38,383 40,040

Intellectual property legal development expenses 1,542 1,767

Acquisition costs 5,153 —

Restructuring and other charges 650 571

Charges related to legal matters, net 694 —

Other operating income (6,941) (5,122)

Operating income 141,772 100,347

Other (expense) income:

Interest expense, net (53,361) (56,939)

Foreign exchange (loss) gain, net (7,800) 4,247

Loss on refinancing (3,510) —

Decrease (increase) in tax receivable agreement liability 2,333 (10,687)

Other income, net 742 518

Total other expense, net (61,596) (62,861)

Income before income taxes 80,176 37,486

Provision for income taxes 2,176 12,868

Net income 78,000 24,618

Less: Net income attributable to non-controlling interests (15,744) (12,423)

Net income attributable to Amneal Pharmaceuticals, Inc. $ 62,256 $ 12,195

Net income per share attributable to Amneal Pharmaceuticals, Inc.’s Class A common stockholders:

Basic $ 0.20 $ 0.04

Diluted $ 0.19 $ 0.04

Weighted-average common shares outstanding:

Basic 316,023 311,054

Diluted 328,933 323,961

Amneal Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(unaudited; in thousands)

March 31, 2026 December 31, 2025

Assets

Current assets:

Cash and cash equivalents $ 197,656 $ 282,029

Restricted cash 4,174 28,842

Trade accounts receivable, net 850,860 895,143

Inventories 641,618 606,302

Prepaid expenses and other current assets 103,091 98,395

Related party receivables 508 470

Total current assets 1,797,907 1,911,181

Property, plant and equipment, net 444,607 442,950

Goodwill 593,800 595,470

Intangible assets, net 534,869 563,498

Operating lease right-of-use assets 46,748 38,832

Operating lease right-of-use assets - related party 14,473 15,216

Financing lease right-of-use assets 52,934 53,328

Other assets 54,880 57,805

Total assets $ 3,540,218 $ 3,678,280

Liabilities and Stockholders’ Deficiency

Current liabilities:

Accounts payable and accrued expenses $ 662,975 $ 761,316

Current portion of liabilities for legal matters 10,550 43,256

Current portion of long-term debt, net 6,200 6,761

Current portion of operating lease liabilities 8,922 8,668

Current portion of operating lease liabilities - related party 2,830 2,705

Current portion of financing lease liabilities 3,533 3,442

Related party payables - short term 33,039 55,485

Total current liabilities 728,049 881,633

Long-term debt, net 2,565,558 2,565,115

Operating lease liabilities 41,101 33,233

Operating lease liabilities - related party 13,467 14,195

Financing lease liabilities 54,876 54,927

Related party payables - long term 456 19,132

Liabilities for legal matters - long term 70,021 71,819

Other long-term liabilities 26,747 32,263

Total long-term liabilities 2,772,226 2,790,684

Redeemable non-controlling interests 85,912 77,292

Total stockholders’ deficiency

(45,969) (71,329)

Total liabilities and stockholders’ deficiency

$ 3,540,218 $ 3,678,280

Amneal Pharmaceuticals, Inc.

Consolidated Statements of Cash Flows

(unaudited; in thousands)

Three Months Ended March 31,

2026 2025

Cash flows from operating activities:

Net income $ 78,000 $ 24,618

Adjustments to reconcile net income to net cash (used in) provided by operating activities:

Depreciation and amortization 43,191 60,159

Unrealized foreign currency loss (gain) 8,215 (3,596)

Amortization of debt issuance costs and discount 3,890 6,811

Reclassification of cash flow hedge 2,878 (6,444)

Loss on refinancing 3,510 —

Stock-based compensation 8,816 7,258

Inventory provision 13,353 23,669

Other operating charges and credits, net 1,486 1,313

Changes in assets and liabilities:

Trade accounts receivable, net 44,013 21,148

Inventories (54,959) (13,263)

Prepaid expenses, other current assets and other assets (13,400) (513)

Related party receivables (56) (2)

Accounts payable, accrued expenses and other liabilities (124,578) (112,626)

Related party payables (41,102) (1,124)

Net cash (used in) provided by operating activities (26,743) 7,408

Cash flows from investing activities:

Purchases of property, plant and equipment (8,175) (13,162)

Acquisition of intangible assets (7,850) (4,200)

Deposits for future acquisition of property, plant and equipment (5,685) (960)

Proceeds from sale of property, plant and equipment — 524

Net cash used in investing activities (21,710) (17,798)

Cash flows from financing activities:

Payments of principal on debt, revolving credit facilities, financing leases and other (140,842) (235,528)

Proceeds from issuance of debt 134,673 —

Payments of deferred financing and refinancing costs (1,982) —

Borrowings on revolving credit facilities — 218,000

Proceeds from exercise of stock options 38 69

Employee payroll tax withholding on restricted stock unit vesting (44,305) (21,639)

Tax and other distributions to non-controlling interests (7,147) (68)

Proceeds from alliance party 510 —

Net cash used in financing activities (59,055) (39,166)

Effect of foreign exchange rate on cash (1,023) (470)

Net decrease in cash, cash equivalents, and restricted cash (108,531) (50,026)

Cash, cash equivalents, and restricted cash - beginning of period 312,939 118,420

Cash, cash equivalents, and restricted cash - end of period $ 204,408 $ 68,394

Cash and cash equivalents - end of period $ 197,656 $ 59,187

Restricted cash - end of period 4,174 6,583

Long-term restricted cash included in other assets - end of period 2,578 2,624

Cash, cash equivalents, and restricted cash - end of period $ 204,408 $ 68,394

Amneal Pharmaceuticals, Inc.

Non-GAAP Reconciliations

(unaudited, in thousands)

Reconciliation of Net Income to EBITDA and Adjusted EBITDA

Three Months Ended March 31, Year Ended

December 31,

2026 2025 2025

Net income $ 78,000 $ 24,618 $ 127,933

Adjusted to add:

Interest expense, net 53,361 56,939 241,091

Provision for income taxes 2,176 12,868 11,276

Depreciation and amortization 43,191 60,159 223,572

EBITDA (Non-GAAP) $ 176,728 $ 154,584 $ 603,872

Adjusted to add (deduct):

Stock-based compensation expense 8,816 7,128 31,823

Acquisition, site closure, and idle facility expenses (1)

5,682 1,241 5,301

Restructuring and other charges 499 571 4,208

Loss on refinancing (2)

3,510 — 31,365

Charges (credit) related to legal matters, net (3)

694 — (390)

Asset impairment charges (4)

— 68 23,022

Foreign exchange loss (gain) 7,800 (4,247) (7,635)

(Decrease) increase in tax receivable agreement liability (2,333) 10,687 6,588

Other (5)

614 (54) (9,739)

Adjusted EBITDA (Non-GAAP) $ 202,010 $ 169,978 $ 688,415

Amneal Pharmaceuticals, Inc.

Non-GAAP Reconciliations

(unaudited, $ in thousands)

Calculation of Net Debt and Net Leverage

March 31, 2026 December 31, 2025

Term Loan Due 2032 $ 2,089,500 $ 2,094,750

Senior Notes Due 2032 600,000 600,000

Gross debt (6)

$ 2,689,500 $ 2,694,750

Less: Cash and cash equivalents 197,656 282,029

Net debt (Non-GAAP) (7)

$ 2,491,844 $ 2,412,721

Adjusted EBITDA (Non-GAAP) Adjusted EBITDA (Non-GAAP)

Year ended December 31, 2025 $ 688,415 $ 688,415

Less: Three months ended March 31, 2025 169,978

Add: Three months ended March 31, 2026 202,010

Last twelve months ended March 31, 2026 $ 720,447

Last Twelve Months Ended

March 31, 2026

Year Ended December 31, 2025

Gross leverage (Non-GAAP) (8)

3.7x 3.9x

Net leverage (Non-GAAP) (9)

3.5x 3.5x

Amneal Pharmaceuticals, Inc.

Non-GAAP Reconciliations

(unaudited; in thousands, except per share amounts)

Reconciliation of Net Income to Adjusted Net Income and Calculation of Adjusted Diluted Earnings Per Share

Three Months Ended March 31,

2026 2025

Net income

$ 78,000 $ 24,618

Adjusted to add (deduct):

Non-cash interest

6,737 334

GAAP provision for income taxes

2,176 12,868

Amortization

29,021 44,274

Stock-based compensation expense

8,816 7,128

Acquisition, site closure, and idle facility expenses (1)

5,682 1,227

Restructuring and other charges

499 571

Loss on refinancing 3,510 —

Charges related to legal matters, including interest, net (3)

1,450 —

Asset impairment charges

— 68

(Decrease) increase in tax receivable agreement liability (2,333) 10,687

Other

614 (44)

Provision for income taxes (10)

(28,755) (22,765)

Net income attributable to non-controlling interests

(15,744) (12,423)

Adjusted net income (Non-GAAP) $ 89,673 $ 66,543

Weighted average diluted shares outstanding (Non-GAAP) (11)

328,933 323,961

Diluted earnings per share (GAAP) $ 0.19 $ 0.04

Adjusted diluted earnings per share (Non-GAAP)

$ 0.27 $ 0.21

Amneal Pharmaceuticals, Inc.

Non-GAAP Reconciliations

(unaudited)

Explanations for Non-GAAP Reconciliations

(1)Acquisition, site closure, and idle facility expenses for the three months ended March 31, 2026 primarily included acquisition costs associated with the announced agreement to acquire Kashiv BioSciences, LLC and rent for vacated properties. Acquisition, site closure, and idle facility expenses for the three months ended March 31, 2025 and year ended December 31, 2025 primarily included costs related to a planned facility closure and rent for vacated properties.

(2)For the year ended December 31, 2025, loss on refinancing was primarily comprised of debt issuance costs associated with the portion of the Term Loan Due 2028 that was modified as part of the Company’s debt refinancing on August 1, 2025. Refer to Note 14. Debt in the Company’s 2025 Annual Report on Form 10-K for information about the Company’s debt as of December 31, 2025.

(3)For the three months ended March 31, 2026, charges related to legal matters, net were $0.7 million, primarily comprised of a $21.2 million charge associated with certain states electing a 25% cash conversion in lieu of product under the Nationwide Opioids Settlement Agreement, partially offset by a $20.8 million discount recorded on the expected settlement payments as of the agreement’s effective date. For the three months ended March 31, 2026, charges related to legal matters, including interest, net included $0.7 million of net charges primarily related to the legal matter discussed above and $0.8 million of interest expense. Refer to Note 19. Commitments and Contingencies in the Company’s 2025 Annual Report on Form 10-K for information about the Nationwide Opioids Settlement Agreement.

(4)For the year ended December 31, 2025, asset impairment charges were primarily related to a Specialty segment product right for which the Company significantly reduced the cash flow forecast after receipt of a complete response letter dated July 22, 2025 from the U.S. Food and Drug Administration regarding a supplemental new drug application.

(5)For the year ended December 31, 2025, the caption “other” primarily reflects a non-recurring, non-operating, non-cash gain.

(6)Refer to Note 14. Debt in the Company’s 2025 Annual Report on Form 10-K for additional information.

(7)Net debt was calculated as the total outstanding principal on the Company’s debt less cash and cash equivalents.

(8)Gross leverage was calculated by dividing gross debt as of March 31, 2026 and December 31, 2025 by adjusted EBITDA for the last twelve months ended March 31, 2026 and year ended December 31, 2025, respectively.

(9)Net leverage was calculated by dividing net debt as of March 31, 2026 and December 31, 2025 by adjusted EBITDA for the last twelve months ended March 31, 2026 and year ended December 31, 2025, respectively.

(10)The non-GAAP effective tax rates for the three months ended March 31, 2026 and 2025 were 24.3% and 25.5%, respectively.

(11)Weighted average diluted shares outstanding for the three months ended March 31, 2026 and 2025 consisted of fully diluted Class A common stock (inclusive of the effect of dilutive securities).

Amneal Pharmaceuticals, Inc.

Non-GAAP Reconciliations

(unaudited, $ in thousands)

Reconciliation of Consolidated GAAP to Non-GAAP Operating Results

Three Months Ended March 31, 2026 Three Months Ended March 31, 2025

As Reported Adjustments Non-GAAP As Reported Adjustments Non-GAAP

Net revenue $ 722,519 $ — $ 722,519 $ 695,420 $ — $ 695,420

Cost of goods sold (1)

402,406 (28,311) 374,095 439,529 (43,515) 396,014

Gross profit 320,113 28,311 348,424 255,891 43,515 299,406

Gross margin % 44.3 % 48.2 % 36.8 % 43.1 %

Selling, general and administrative (2)

138,860 (11,281) 127,579 118,288 (9,547) 108,741

Research and development (3)

38,383 (773) 37,610 40,040 (1,480) 38,560

Intellectual property legal development expenses 1,542 — 1,542 1,767 — 1,767

Acquisition costs (4)

5,153 (5,153) — — — —

Restructuring and other charges 650 (499) 151 571 (571) —

Charges related to legal matters, net

694 (694) — — — —

Other operating income (6,941) — (6,941) (5,122) — (5,122)

Operating income $ 141,772 $ 46,711 $ 188,483 $ 100,347 $ 55,113 $ 155,460

(1) Adjustments for the three months ended March 31, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($1.0 million and $0.9 million), amortization expense ($27.3 million and $42.5 million), and asset impairment charges (none and $0.1 million).

(2) Adjustments for the three months ended March 31, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($7.0 million and $5.4 million), amortization expense ($2.7 million in each period), site closure costs ($0.5 million in each period), and other ($1.1 million and $0.9 million).

(3) Adjustments for the three months ended March 31, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($0.8 million in each period) and site closure costs (none and $0.7 million).

(4) Acquisition costs for the three months ended March 31, 2026 primarily included acquisition costs associated with the announced agreement to acquire Kashiv BioSciences, LLC.

Amneal Pharmaceuticals, Inc.

Affordable Medicines Segment

Reconciliation of GAAP to Non-GAAP Operating Results (1)

(unaudited; $ in thousands)

Three Months Ended March 31, 2026 Three Months Ended March 31, 2025

As Reported Adjustments Non-GAAP As Reported

Adjustments

Non-GAAP

Net revenue $ 423,237 $ — $ 423,237 $ 414,708 $ — $ 414,708

Cost of goods sold (2)

232,444 (9,570) 222,874 242,633 (10,875) 231,758

Gross profit 190,793 9,570 200,363 172,075 10,875 182,950

Gross margin % 45.1 % 47.3 % 41.5 % 44.1 %

Selling, general and administrative (3)

41,318 (2,432) 38,886 33,715 (1,816) 31,899

Research and development (4)

33,286 (677) 32,609 30,980 (689) 30,291

Intellectual property legal development expenses 1,493 — 1,493 1,713 — 1,713

Charges related to legal matters, net 694 (694) — — — —

Other operating income (6,941) — (6,941) (5,122) — (5,122)

Operating income $ 120,943 $ 13,373 $ 134,316 $ 110,789 $ 13,380 $ 124,169

(1)Revenue, cost of goods sold, and gross profit from the sale of Amneal products by AvKARE were included in our Affordable Medicines segment.

(2)Adjustments for the three months ended March 31, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($1.0 million and $0.9 million), amortization expense ($8.6 million and $9.9 million), and asset impairment charges (none and $0.1 million).

(3)Adjustments for the three months ended March 31, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($1.9 million and $1.3 million) and site closure costs ($0.5 million in each period).

(4)Adjustments for the three months ended March 31, 2026 and 2025 were comprised of stock-based compensation expense.

Amneal Pharmaceuticals, Inc.

Specialty Segment

Reconciliation of GAAP to Non-GAAP Operating Results

(unaudited; $ in thousands)

Three Months Ended March 31, 2026 Three Months Ended March 31, 2025

As Reported Adjustments Non-GAAP As Reported Adjustments Non-GAAP

Net revenue $ 133,265 $ — $ 133,265 $ 108,297 $ — $ 108,297

Cost of goods sold (1)

43,020 (18,741) 24,279 53,083 (32,640) 20,443

Gross profit 90,245 18,741 108,986 55,214 32,640 87,854

Gross margin % 67.7 % 81.8 % 51.0 % 81.1 %

Selling, general and administrative (2)

34,691 (526) 34,165 30,978 (345) 30,633

Research and development (3)

5,097 (95) 5,002 9,060 (791) 8,269

Intellectual property legal development expenses 49 — 49 54 — 54

Restructuring and other charges 347 (347) — 130 (130) —

Operating income $ 50,061 $ 19,709 $ 69,770 $ 14,992 $ 33,906 $ 48,898

(1)Adjustments for the three months ended March 31, 2026 and 2025 were comprised of amortization expense.

(2)Adjustments for the three months ended March 31, 2026 and 2025 were comprised of stock-based compensation expense.

(3)Adjustments for the three months ended March 31, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($0.1 million in each period) and site closure costs (none and $0.7 million).

Amneal Pharmaceuticals, Inc.

AvKARE Segment

Reconciliation of GAAP to Non-GAAP Operating Results (1)

(unaudited; $ in thousands)

Three Months Ended March 31, 2026 Three Months Ended March 31, 2025

As Reported Adjustments Non-GAAP As Reported Adjustments Non-GAAP

Net revenue $ 166,017 $ — $ 166,017 $ 172,415 $ — $ 172,415

Cost of goods sold 126,942 — 126,942 143,813 — 143,813

Gross profit 39,075 — 39,075 28,602 — 28,602

Gross margin % 23.5 % 23.5 % 16.6 % 16.6 %

Selling, general and administrative (2)

16,680 (2,648) 14,032 15,694 (2,700) 12,994

Operating income $ 22,395 $ 2,648 $ 25,043 $ 12,908 $ 2,700 $ 15,608

(1)Revenue, cost of goods sold, and gross profit from the sale of Amneal products by AvKARE were included in our Affordable Medicines segment.

(2)Adjustments for the three months ended March 31, 2026 and 2025 were comprised of amortization expense.

GRAPHIC

Filename: image.jpg · Sequence: 6

Binary file (3187 bytes)

Download image.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Document and Entity Information Document

May 07, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 07, 2026

Entity Registrant Name

AMNEAL PHARMACEUTICALS, INC.

Entity Central Index Key

0001723128

Entity Emerging Growth Company

false

Entity File Number

001-38485

Entity Incorporation, State or Country Code

Entity Tax Identification Number

93-4225266

Entity Address, Address Line One

400 Crossing Blvd

Entity Address, City or Town

Bridgewater

Entity Address, State or Province

Entity Address, Postal Zip Code

08807

City Area Code

908

Local Phone Number

947-3120

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Class A Common Stock, par value $0.01 per share

Trading Symbol

AMRX

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration